Question:
Core tablet coated with cellulose acetate phthalate has been administered to a patient. Where do you expect the drug to be released:
Core tablet coated with cellulose acetate phthalate has been administered to a patient. Where do you expect the drug to be released:
Show Hint
Cellulose acetate phthalate (CAP) coatings are commonly used for enteric coatings, ensuring drug release in the intestine where the pH is more favorable for the dissolution of the coating.
Updated On: Feb 4, 2025
- Liver
- Intestine
- Oral cavity
- Stomach
Hide Solution
Verified By Collegedunia
The Correct Option is B
Solution and Explanation
Cellulose acetate phthalate (CAP) is a pH-sensitive coating that is designed to dissolve in the intestine, which has a higher pH compared to the stomach. This allows the drug to be released in the intestine, avoiding degradation in the acidic environment of the stomach.
Was this answer helpful?
0
0
Top Questions on Tablets
- Coating of Eudragit NE40D on tablets is done to prepare:
- Core tablet coated with cellulose acetate phthalate has been administered to a patient. Where do you expect the drug to be released:
- Coating of Eudragit NE40D on tablets is done to prepare:
- Which of the following is/are in-process QC test(s) for tablets:
- The rate limiting step for the absorption of controlled release tablet is the:
View More Questions
Questions Asked in GPAT exam
- Match the following:
(P) Schedule H
(Q) Schedule G
(R) Schedule P
(S) Schedule F2
Descriptions:
(I) Life period of drugs
(II) Drugs used under RMP
(III) List of Prescription Drugs
(IV) Standards for surgical dressing- GPAT - 2025
- Drug therapy
- Minimum manufacturing space for 'Habb-Unani medicine' as per Schedule of D and C Act?
- GPAT - 2025
- Pharma Techniques
- If the label or the container bears the name of an individual or company purporting to be the manufacturer of the drug, which individual or company is fictitious or does not exist, it is:
- GPAT - 2025
- Drug therapy
- Match the following:
(1) Schedule FF
(2) Schedule F3
(3) Schedule V
(4) Schedule Y
Descriptions:
(P) Standards of patent and proprietary medicines
(Q) Requirements and guidelines for clinical trials
(R) Standards for sterilized umbilical tapes
(S) Standards for Ophthalmic preparations- GPAT - 2025
- Drug therapy
Match the following Class and their Drug:
(1) Alkylating (P) 5-fluorouracil
(2) Platinum analog (Q) Cisplatin
(3) Antimetabolite (R) Cetuximab
(4) EGF receptor inhibitor (S) Chlorambucil- GPAT - 2025
- Biostatistics and Research Methodology
View More Questions